muscle wasting with glp 1 Weighing the risk of GLP-1 treatment in older adults: Should we be concerned about sarcopenic obesity? Creatine for GLP-1 Users: Science-Backed
Description
Chronic inflammation in type 2 diabetes (T2D), characterized by constitutively activated immune cells and elevated pro-inflammatory mediators along with hyperglycaemia and increased free fatty acids and branched chain amino acid levels, significantly alters the immuno-metabolic axis
Physicians on Sermo share experiences with GLP-1 weight loss drugs and risks
Usage: Twice daily, 2 mL each time
Industry Implications CDMO & Pen Makers: Shailys expansion signals profitable growth in device manufacturing Generic Drug Makers: Need to scale peptide production and align launch timelines with pen availability Global Access Shift: Pen-device supply becomes a bottleneck unless proactively expanded Recommended Actions for Pharma Stakeholders 1
Each pack includes 30 patches for a full one-month supply
